Shares of Greenwich LifeSciences Inc. (GLSI) have been on a tear over the past ten days as the clinical-stage biotech pushes ahead with its financing strategy and prepares to implement risk-reducing modifications to the phase III trial of its investigational breast cancer immunotherapy, GLSI-100, upon the regulatory go-ahead.GLSI-100 is a combination of GP2 peptide vaccine and GM-CSF, an immune system booster, which is designed to help the body recognize and fight cancer cells that express the HER2/neu pro ...